查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138369

全球結膜炎治療市場-2022-2029

Global Conjunctivitis Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

新興國家結膜炎的流行是預測期內推動全球市場的因素之一。性傳播疾病 (STD) 患病率的上升也被認為是在預測期內推動全球市場的因素之一。衛生條件差、早產和母體性傳播感染等因素是新生兒結膜炎的一些危險因素。新興國家對該疾病治療的認識不足和這些國家的藥物覆蓋面窄是在預測期內限制全球新生兒結膜炎治療市場的一些因素。

此外，全球主要城市日益嚴重的空氣污染也在推動市場發展。根據世界銀行 2021 年的數據，空氣污染造成的健康成本約為 8.1 萬億美元，相當於全球 GDP 的 6.1%。先前的幾項研究表明，環境空氣污染會加劇結膜炎和過敏性結膜炎。這是由於結膜對環境顆粒的敏感性以及結膜與外部環境的直接接觸。因此，日益嚴重的空氣污染正在推動全球結膜炎治療市場的發展。

C. Michael Gibson 教授於 2020 年發表了結膜炎流行病學和人口統計，指出病毒性結膜炎通常影響成人，而細菌性結膜炎則影響兒童。 1 歲以下兒童（每 100,000 名患者 8,000 人）感染性結膜炎的發病率高於 4 歲以下兒童（每 100,000 名患者 1,200 人）。這種病很常見，也很容易治療。此外，這種疾病通常是可自我診斷的，很少需要診斷測試。

即使在印度這樣的國家，結膜炎的患病率也很高。例如，2020 年 2 月 2 日，泰米爾納德邦通知學校學生和教職員工存在病毒性結膜炎問題。

提高公眾對該疾病及其治療的認識也提振了市場。幾個州正在積極促進結膜炎的治療。治療劑的容易獲得也推動了市場的發展。在預測期內，可支配收入的增加也推動了市場增長。

但是，我們預計未來幾年將面臨專利懸崖。某些具有成本效益的仿製藥的供應可能會嚴重阻礙市場增長。缺乏可用於臨床前和臨床試驗的新型化合物正在影響市場增長。對在研藥物和細菌性結膜炎批准的研究較少，正在影響預測期內的市場增長。

此外，據信在全球範圍內爆發的 COVID-19 大流行對全球市場的增長產生了負面影響。儘管結膜炎患者感染病毒性結膜炎（通常由腺病毒引起）的風險較高，但預計市場將下降。冠狀病毒會引起一些類似的眼部症狀和體徵，包括結膜炎感染、水樣分泌物、畏光和眼睛刺激，而腺病毒會導致結膜炎感染、水樣分泌物、畏光和眼睛刺激。可能會導致眼睛症狀和體徵，包括眼睛刺激。

由於世界各國政府嚴格關閉，非危及生命的醫療預約被推遲或取消，每年這個時候開出的結膜炎處方減少，限制了市場增長。預計這一因素將阻礙預測期內的市場增長。

區域介紹

按地區劃分，結膜炎治療市場分為北美、南美、歐洲、亞太地區、中東和非洲。在所有地區中，北美在全球結膜炎治療市場中占主導地位，由於結膜炎治療市場存在眾多主要參與者，預計在預測期內將以最高的複合年增長率增長。

根據美國國立衛生研究院的數據，美國每年有超過 600 萬人患有結膜炎。該疾病的估計成本每年約為 3.77 億美元至 8.57 億美元。結膜炎是該國最常見的疾病，影響 15% 至 40% 的人口，並且發現在春季和夏季多發。由於其發達的醫療服務和結膜炎的高發病率，預計美國將在預測期內佔最大份額。根據美國哮喘和過敏基金會的數據，每年有超過 5000 萬人經歷各種類型的過敏症。在這 5000 萬人中，估計美國約有 650 萬人患有急性結膜炎。預計這些因素將推動整個地區的市場增長。

由於傳染病流行、發展中國家的衛生條件差以及該地區一些國家的長期交付量增加，預計亞太地區將佔據第三大份額。此外，印度、中國和馬來西亞等國家正在經歷蓬勃發展的醫療旅遊業，預計這將提振治療需求。在預測期內，這些因素正在刺激該地區的市場增長。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 按疾病類型劃分的市場細分
  • 按藥物類別劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 患有結膜炎的人數增加
      • 易於獲得治療藥物
    • 抑制因素
      • 替代療法的可用性，例如家庭療法
  • 影響分析
  • 機會

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 產品分析
  • COVID-19 影響分析

第 6 章按疾病類型

  • 過敏性結膜炎
  • 細菌性結膜炎
  • 病毒性結膜炎

第 7 章按藥物類別

  • 抗生素
  • 眼科類固醇
  • 非甾體抗炎藥 (NSAIDS)
  • 抗組胺藥
  • 其他

第 8 章最終用戶

    • 醫院
  • 專科診所
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲
  • 南美洲
    • 終端用戶市場規模分析及同比增長率分析（%）（單位：百萬日元）
      • 巴西
      • 阿根廷
      • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 11 章公司簡介

  • Boehringer Ingelheim GmbH
    • 公司簡介
    • 產品組合和描述
    • 主要發展狀況
    • 財務摘要
  • Allergan Inc.
  • Sanofi-Aventis
  • Novartis AG
  • Bausch & Lomb Inc.
  • CIBA Vision Ophthalmics
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Santen Pharmaceuticals Co. Ltd.
  • Akron Incorporated（*List is not exhaustive）

第 12 章重要注意事項

第 13 章數據智能

簡介目錄
Product Code: DMPH2682

Market Overview

The Conjunctivitis Treatment market was valued at USD 3,750.60 million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 3.88% during the forecast period (2022-2029).

Conjunctivitis is a common condition that causes redness and inflammation of the thin layer of tissue that covers the front of the eye. It can be highly contagious. But it's rarely serious. It's very unlikely to damage the vision. Conjunctivitis caused by some bacteria and viruses can spread easily from person to person, but it isn't a serious health risk if diagnosed promptly. If it happens in a newborn baby, though, tell a doctor right away, as it might be an infection that threatens the baby's vision.

Allergies are also a common cause of conjunctivitis. The cells in the conjunctiva can react to an allergen. Some examples of allergens include grass, dust, animal fur, and mascara. Both viral and bacterial conjunctivitis can occur along with colds or symptoms of a respiratory infection, such as a sore throat. Other symptoms of conjunctivitis include itchiness and watering of the eyes, and sometimes a sticky coating on the eyelashes.

Conjunctivitis caused by Chlamydia trachomatis or Neisseria gonorrhoeae requires aggressive antibiotic therapy, but conjunctivitis due to other bacteria is usually self-limited. Chronic conjunctivitis is usually associated with blepharitis, recurrent styes, or meibomianitis. Treatment requires good eyelid hygiene and the application of topical antibiotics as determined by culture. Allergic conjunctivitis is distinguished by severe itching and allergen exposure.

Market Dynamics

The market is driven is the increasing prevalence of conjunctivitis in developing countries is one of the factors driving the global market during the forecast period. The surge in the prevalence of sexually transmitted diseases (STDs) is another factor likely to propel the global market during the forecast period. Factors such as poor hygiene conditions, premature deliveries, and maternal sexually transmitted infection are some of the risk factors for neonatal conjunctivitis. Lack of awareness about the treatment of the disease in developing countries and lack of coverage of medicines in these countries are some of the factors restraining the global neonatal conjunctivitis treatment market during the forecast period.

The market is also driven by rising air pollution in major cities across the globe. According to the world bank published in 2021, Air pollution is responsible for health costs of around 8.1 trillion US$, equivalent to 6.1 percent of the global GDP. Some earlier research studies have proven that ambient air pollution can aggravate conjunctivitis and allergic conjunctivitis. This is attributed to the conjunctiva being sensitive to environmental particles along with direct contact of the conjunctiva with the outside environment. Hence, the rise in air pollution propels the global conjunctivitis treatment market.

Professor C. Michael Gibson M.S., M.D, has published Conjunctivitis epidemiology and demographics, in 2020, viral conjunctivitis commonly affects adults, and bacterial conjunctivitis affects children. The incidence of infective conjunctivitis is higher in children less than 1-year-old (8,000 cases per 100,000 patients) than in children less than 4 years of age (1,200 cases per 100,000 patients). The disease is very common, and treatment for the same is easily available. Most of the time, the disease is self-diagnosable, and there is least need to undergo any diagnostic test for this disease.

Countries like India are also having a high prevalence of conjunctivitis. For instance, on 2nd February 2020, Tamil Nadu state notified that viral conjunctivitis problem among the student and staff in school.

A rise in awareness among people about the disease and its treatment is also boosting the market. Several states are actively promoting the treatment of the disease. Easy availability of the treatment is boosting the market. The rise in disposable income is also driving the growth of the market in the forecast period.

However, the market is expecting to face a patent cliff in the coming years. The availability of certain cost-effective generic medicines is likely to hamper the market growth extensively. The scarcity of novel compounds available for preclinical and clinical examination is affecting the growth of the market. The dearth of investigations regarding approval of drugs and bacterial conjunctivitis in the pipeline is affecting the market growth in the forecast period.

Moreover, the outbreak of the COVID-19 pandemic across the globe is set to negatively impact the global market growth. Despite the patients suffering from conjunctivitis tend to be at a high risk of getting injected by viral conjunctiva that is usually caused because of adenovirus, the market is expected to undergo a decline. While coronavirus also causes several similar ocular signs and symptoms, such as conjunctivitis infection, watery discharge, photophobia, and eye irritation.

Due to the stringent lockdowns imposed by governments across the globe, the postponement or cancellations of non-life-threatening medical visits is expected to restrict the market growth as lesser prescriptions for conjunctivitis will be issued in this period. This factor will hamper the market growth in the forecast period.

Market Segmentation:

The global conjunctivitis treatment market is segmented based on disease type into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment held the largest market share. Allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. People having allergies are more likely to develop allergic conjunctivitis.

As stated by the Asthma and Allergy Foundation of America, approximately 30% of adults and 40% of children suffer from allergies in the United States. The diagnosis of the disease is usually done by self. However, if someone is unable to identify the disease, there are certain tests that the doctor performs to understand the disease and its cause. Some of the tests include allergy skin tests, a blood test to see if the patient's body is producing proteins, or antibodies, to protect itself against specific allergens like mold or dust. This factor will drive the growth of the market in the forecast period.

Moreover, the National Institutes of Health (NIH) indicated that the number of patients being diagnosed with allergic conjunctivitis is increasing globally. This increase in incidence rate propels the global allergic conjunctivitis treatment market. Pharmaceutical companies are developing new treatment options for allergic conjunctivitis such as Zerviate, EM-100, ADX-102, PRT-2761, and OTX-DP. For instance, EyeMax LLC's EM-100 is currently in phase 3 of a clinical trial, where its effectiveness is being checked in the treatment of ocular itching. Presently, around two-third of new treatment options are in phase 2 or 3 of clinical trials. All these studies are being sponsored by major pharmaceutical companies. These factors are driving the growth of the market in the forecast period.

The bacterial conjunctivitis segment is expected to have positive market growth in the forecast period. Bacterial conjunctivitis is one of the major eye problems encountered worldwide and are caused by bacteria such as Moraxella and Chlamydia trachomatis. These bacteria are responsible for causing persistent conjunctivitis with a higher level of redness. Most of the cases of bacterial conjunctivitis are acute and self-limiting and not a major cause of serious health problems however, due to its high prevalence the infection can have a large impact on society as individuals tend to miss their school or work.

The increasing cases of bacterial conjunctivitis demand efficient medication, which supports the growth of the bacterial conjunctivitis drugs market. Bacterial conjunctivitis spreads because of poor hygiene, immune compromise, and ocular diseases such as dry eye, blepharitis, and contaminated cosmetics. It can be prevented by maintaining proper hygiene and also hand wash reduces the chances of bacterial conjunctivitis. This factor will drive the growth of the market in the forecast period.

Further, the market is also classified based on drug class as antibiotics, ophthalmic steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antihistamines, others. The antibiotics segment is held the largest market share. Antibiotics may help shorten the length of infection, reduce complications, and reduce the spread to others. Antibiotics may be necessary for people whose immune system is compromised. In certain cases where an underlying infection elsewhere in the body may be causing conjunctivitis symptoms, you may be prescribed antibiotics to swallow in tablet form. Standard antibiotic treatments often will work for ordinary bacterial infections related to staphylococcus (staph) or streptococcus (strep) infections, which are the usual causes of bacterial conjunctivitis in adults. This factor will drive the growth of the market in the forecast period.

Typical antibiotic treatment often will work for these types of bacterial infections without the need to swab the eye and send off a sample (culture) for evaluation. If the initial treatment doesn't work, then a culture may be needed so that treatment can be changed to a more specialized type of antibiotic.

Geographical Presentation

By region, the conjunctivitis treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global conjunctivitis treatment market and is expected to grow at the highest CAGR during the forecast period due to the presence of a large number of key players operating in the conjunctivitis treatment market.

According to the National Institute of Health that conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer. Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share in the forecast period. According to the Asthma and Allergy Foundation of America, more than 50 million people experienced with various types of allergies in every year. In the 50 million people, estimated approximately around 6.5 million people that acute conjunctivitis affects in the United States. These factors are expected to fuel the overall market growth across the region.

The Asia-Pacific region is expected to have the third-largest share due to an increase in the prevalence of infections, poor hygiene conditions in developing countries, and prolonged deliveries in some of the countries in the region. Furthermore, the booming medical tourism industry in countries such as India, China, and Malaysia are expected to boost demand for the treatment. These factors stimulate market growth over the forecasted period in the region.

Competitive Landscape:

The conjunctivitis treatment market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Novartis AG, Bausch & Lomb Inc., CIBA Vision Ophthalmic, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the conjunctivitis treatment market across the globe.

For instance, On 25th February 2021, Allergan, an AbbVie company, submitted its new drug application for investigational AGN-190584 for the Treatment of Presbyopia. The most common treatment-emergent non-serious adverse events occurring at a frequency of ≥5% in AGN-190584 treated participants were headache and conjunctival hyperemia.

On 30th June 2022, Novartis acquired the Kedalion Therapeutics AcuStream platform, a topical ocular delivery device used to facilitate dosing support and the delivery of front-of-eye therapies.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Drug Class
  • 3.3. Market Snippet by End users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Number of People Suffering From Conjunctivitis
      • 4.1.1.2. Easy Availability of the Treatment
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Alternative Treatments Such as Home Remedies
  • 4.2. Impact Analysis
  • 4.3. Opportunity

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Product Analysis
  • 5.6. COVID-19 Impact Analysis

6. By Disease Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.3. Market Attractiveness Index, By Disease Type
    • 6.3.1. Allergic Conjunctivitis *
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
    • 6.3.2. Bacterial Conjunctivitis
    • 6.3.3. Viral Conjunctivitis

7. By Drug Class

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.3. Market Attractiveness Index, By Disease
    • 7.3.1. Antibiotics
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
    • 7.3.2. Ophthalmic Steroids
    • 7.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 7.3.4. Antihistamines
    • 7.3.5. Others

8. By End-users

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users Market Attractiveness Index, By End-users
    • 8.2.1. Hospitals
    • 8.2.2. Introduction
    • 8.2.3. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
  • 8.3. Specialty Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. U.S.
      • 9.4.6.2. Canada
      • 9.4.6.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. Germany
      • 9.5.6.2. U.K.
      • 9.5.6.3. France
      • 9.5.6.4. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.5. . Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.6.1. Brazil
      • 9.6.6.2. Argentina
      • 9.6.6.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),End-users
    • 9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.6.1. China
      • 9.7.6.2. India
      • 9.7.6.3. Japan
      • 9.7.6.4. Australia
      • 9.7.6.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Boehringer Ingelheim GmbH *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Developments
    • 11.1.4. Financial Overview
  • 11.2. Allergan Inc.
  • 11.3. Sanofi-Aventis
  • 11.4. Novartis AG
  • 11.5. Bausch & Lomb Inc.
  • 11.6. CIBA Vision Ophthalmics
  • 11.7. Pfizer Inc.
  • 11.8. Merck & Co., Inc.
  • 11.9. Santen Pharmaceuticals Co. Ltd.
  • 11.10. Akron Incorporated(*List is not exhaustive)

12. Premium Insights

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us